Laura Joszt, MA

Laura Joszt headshot

Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars®. She has been working on AJMC since 2014 and has been with AJMC’s parent company, MJH Life Sciences®, since 2011.

She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.

Articles by Laura Joszt, MA

There are multiple factors that can affect how patients respond to treatment or how their health is maintained. One that is gaining more attention is how social interactions can benefit a person’s health.

With 2 more Republicans announcing that they oppose the Senate healthcare bill, Senate Majority Leader Mitch McConnell (R-Kentucky) no longer has enough votes to pass the Better Care Reconciliation Act of 2017, which would repeal and replace parts of the Affordable Care Act.

Whipple’s disease (WD) is a rare disease that predominantly affects middle-aged white men, and its diagnosis is often delayed because it is misdiagnosed as rheumatoid arthritis. A new study in Orphanet Journal of Rare Diseases aimed to describe clinical symptoms of WD and appropriate treatment.

On Thursday, the House of Representatives passed a bill that would reform medical malpractice by capping noneconomic damages at $250,000. Supporters say the reform would reduce frivolous claims and prevent doctors from practicing costly defensive medicine. Here’s a look at 5 aspects of medical malpractice in the United States.

With half a year behind us, The American Journal of Managed Care® (AJMC®) is reflecting back on the journal articles published through all journals in the franchise over the first half of 2017. The topics of interest ranged from alternative payment models to yoga and all focused on providing better care and better outcomes for patients.

With the year 2017 halfway over, The American Journal of Managed Care® is looking back at the news of the first half of the year. Here we bring you the most read news stories, including conference coverage, a take on the new president’s first executive order, reimbursement challenges, and more.

Republican leaders in the Senate unveiled a long-awaited healthcare reform bill, called the Better Care Reconciliation Act of 2017, that will roll back the Affordable Care Act’s taxes and Medicaid expansion, although at a slower timeline than included in the House of Representatives’ American Health Care Act, which was passed on May 4 by a vote of 217-213.

AJMCtv® interviews let you catch up with experts on what’s new and important about changes in healthcare. The interviews provide insights from key decision makers-from the clinician to the health plan leader to the regulator. When every minute in your day matters, AJMCtv® interviews keep you informed. You can access the video clips at www.ajmc.com/interviews.

With the sustainability and affordability of the US healthcare system in dire straits, now is the time for collaboration on new payment models, explained chief executive officers from a health plan and an insurer during a general session on the second day of America’s Health Insurance Plans’ Institute & Expo, held June 7-9 in Austin, Texas.

The United States is only slightly halfway through its healthcare transformation, claimed Mike Leavitt, founder and partner of Leavitt Partners and the former governor of Utah, during a general session on the first day of America’s Health Insurance Plans Institute & Expo, held June 7-9, in Austin, Texas.

During a general session at America’s Health Insurance Plans’ Institute & Expo, held June 7-9 in Austin, Texas, Eric Topol, MD, explained the buzz behind precision medicine and why it is needed to combat the harms of imprecision in medicine.

Patients with cystic fibrosis face a lifetime of time-consuming treatment. There are new breakthrough therapies that not only treat symptoms of the disease, but also the underlying causes, which represents a source of hope for patients. However, barriers to treatment still stand in the way, according to a new white paper from the Cystic Fibrosis Engagement Network.

The notion of letting Medicare negotiate drug prices has been around for years, but has recently gained new traction under President Donald Trump. Panelists at the ISPOR 22nd Annual International Meeting, held May 20-24 in Boston, Massachusetts, discussed the complexities of allowing Medicare to negotiate prices and whether or not it would produce meaningful savings.



Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo